

0960-894X(93)E0077-E

## DIFFERENTIAL BINDING AND DOPAMINE UPTAKE ACTIVITY OF COCAINE ANALOGUES MODIFIED AT NITROGEN

Johannes Stoelwinder,<sup>a</sup> Marinella Roberti,<sup>a</sup> Alan P. Kozikowski,<sup>a\*</sup> Kenneth M. Johnson,<sup>b</sup> and John S. Bergmann<sup>b</sup>

<sup>a</sup>Neurochemistry Research, Mayo Foundation for Medical Education and Research, 4500 San Pablo Road, Jacksonville, Florida 32224, and <sup>b</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-1031.

**Abstract:** Syntheses of a variety of new N-modified cocaine analogues are reported together with their binding affinities and dopamine uptake inhibition activities. Compounds 3 and 13, which exhibit discrepancies in their binding and uptake potencies, were tested for their ability to antagonize cocaine's inhibition of dopamine reuptake.

In our continuing efforts to examine the structure-activity relationships (SAR) of a broad variety of cocaine derivatives, we have reported recently that methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine reuptake activity, with several of these compounds being more active in the binding experiments than in dopamine uptake inhibition. These results suggested that it may indeed be possible to design a functional antagonist of cocaine through structural modifications of the cocaine molecule. Since the nitrogen atom in cocaine is important for potent binding to the cocaine recognition site associated with the dopamine transporter, and the substituent at nitrogen can be modified readily, we felt that it would be worthwhile to synthesize various new N-modified cocaine analogues and to examine both their binding affinities and their ability to inhibit dopamine reuptake.

As has become evident from earlier studies, substitution at nitrogen can have a large effect on activity, in particular when changes of the electron density at nitrogen are involved.<sup>2</sup> This was demonstrated by the conversion of the cocaine N-methyl group to its methiodide salt bearing a formal positive charge on nitrogen which resulted in 100-fold reduction in activity. Replacement of the N-methyl group with an electron withdrawing acetyl group resulted in a compound of 30-fold reduced

binding affinity. The use of electronically similar but sterically larger groups such as propyl or benzyl in the replacement of the N-methyl group of cocaine reduced the activity by only 0-7-fold. Additionally, Reith *et al.* found that both norcocaine 1 and *N*-allyl-*N*-norcocaine had only slightly reduced binding affinities relative to cocaine as measured in the cortex or striatum.<sup>3</sup> The binding properties of three N-modified 4-fluorophenyl tropanes ("Win" series, allyl, propyl and hydrogen in place of N-methyl) were previously reported by Madras *et al.* who showed that all three compounds were more potent than cocaine in displacing [ $^{3}$ H]cocaine from its binding sites. Comparison with the parent  $^{2}$ β-carbomethoxy- $^{3}$ β-(4-fluorophenyl)tropane (Win 35428), however, showed that the potency was decreased.<sup>4</sup> Thus, these studies reveal that replacement of the N-methyl group of cocaine with sterically larger groups has relatively small effects on the binding potency, unless the electron density on nitrogen is decreased, which then results in a greater loss in activity.

The structures of our newly synthesized *N*-modified cocaine derivatives can be divided into two groups: *N*-norcocaine compounds with a nitrogen-nitrogen bond (Scheme 1), and cocaine derivatives with a functionalized N-methyl group (Scheme 2). The cocaine analogues with an N-N bond were

Scheme 1. Synthesis of N-N-functionalized cocaine analogues.

prepared from *N*-norcocaine 1 (Scheme 1).<sup>5</sup> Treatment of 1 with nitrous acid yielded *N*-nitroso-*N*-norcocaine 2, which was easily oxidized to the N-nitro compound 3 by the action of hydrogen peroxide in trifluoroacetic acid.<sup>6</sup> Attempts to introduce an amino group by reduction of the nitroso group of 2 were unsuccessful, for *N*-acetylamino-*N*-norcocaine 4 was formed instead.<sup>7</sup> Direct introduction of the N-amino group in 5 with hydroxylamine-*O*-sulfonic acid (HOSA)<sup>8</sup> resulted in

formation of the tricyclic lactam 7, most likely by initial formation of hydrazine 6, followed by intramolecular attack on the carbomethoxy group.

The cocaine derivatives 9, 11, and 13 were all prepared by direct alkylation of the secondary amino group of *N*-norcocaine 5. Accordingly, alkylation with *O*-ethoxyethyl protected 2-bromoethanol yielded intermediate 8, which upon treatment with hydrochloric acid was deprotected to give compound 9. Compound 11 was prepared by alkylation with methyl bromoacetate, and compound 13 was prepared by alkylation with benzyl bromoacetate followed by hydrogenolytic removal of the benzyl group.

Scheme 2. Synthesis of N-methyl functionalized cocaine analogues.

From the binding and dopamine uptake data presented in Table 1, it is clear that extension of the N-methyl group with a functionalized carbon chain as in 9, 11, and 13 leads to binding affinities not much different from that of cocaine. These data can be rationalized by the fact that the electron withdrawing functional groups are insulated from the nitrogen atom by one or two carbon atoms, and thus the effect of the hydroxyl group of 9, the carbomethoxy group of 11, and the carboxylic acid group of 13 is too small to have a pronounced influence on the binding affinity. Since the K<sub>i</sub>s for the binding of compounds 9, 11, and 13 are 2.2, 3.3, and 5.5 times smaller than the K<sub>i</sub>s for inhibition of dopamine reuptake, respectively, it is possible that such analogues may be capable of countering to some extent the effects of cocaine (however, see below).

As shown in Table 1, exchange of the N-methyl group with a functional group containing a nitrogen-nitrogen bond leads to a much more pronounced change in binding potency. All of the compounds 2, 3, 4, and 7 show lower binding affinities in comparison to (-)-cocaine, ranging from a factor of more than one thousand for N-aminoacetyl-N-norcocaine 4 to a five-fold decrease in binding affinity for N-nitro-N-norcocaine 3. In these cases the functional groups are directly connected to the

**Table 1.**  $K_i$  values ( $\mu$ M)  $\pm$  S.E.M. for cocaine and compounds **2-13** on [ $^3$ H]dopamine uptake and [ $^3$ H]mazindol binding in rat corpus striatum P2 synaptosomes.

Compound	[ <sup>3</sup> H]Dopamine uptake; (n)	[ <sup>3</sup> H]Mazindol Binding; (n)
(-)-cocaine	0.32 ± 0.01; (12)	$0.28 \pm 0.0$ ; (4)
O <sub>2</sub> N CO <sub>2</sub> Me	231.7 ± 39.5; (3)ª	99.5 ± 12.3; (3) <sup>b</sup>
CO <sub>2</sub> Me	21.2 ± 0.6; (3)	7.5 ± 0.9; (3)
NHCOCH <sub>3</sub> NCO <sub>2</sub> Me	> 1000; (1) <sup>c</sup>	> 1000; (2) <sup>d</sup>
7	115.0 ± 15.7; (2)	44.9 ± 6.2; (3) <sup>e</sup>
CH <sub>2</sub> CH <sub>2</sub> OH.HCI	1.6 ± 0.2; (3)	0.7 ± 0.1; (3)
CH <sub>2</sub> CO <sub>2</sub> Me.HCI	1.6 ± 0.1; (3)	0.48 ± 0.04; (3)
CH <sub>2</sub> CO <sub>2</sub> H.HCI CO <sub>2</sub> Me	2.1 ± 0.4; (3)	0.38 ± 0.02; (3)

(a) maximum inhibition at 1000  $\mu$ M = 77 %; (b) maximum inhibition at 1000  $\mu$ M = 82 %; (c) maximum inhibition at 1000  $\mu$ M = 41 %; (d) maximum inhibition at 1000  $\mu$ M = 42 %; (e) maximum inhibition at 1111  $\mu$ M = 83 %.

nitrogen atom, therefore any electronic perturbation caused by these functionalities should have a much more pronounced effect on the binding affinity. Since the functional groups in the N-N series are all electron withdrawing, this explains the overall decrease in binding affinity. However, two of the analogues, with the N-methyl group replaced by the nitroso group (2) or the nitro group (3) were found to be of particular interest. We observed that replacement of the electron withdrawing nitroso group of 2 with the more electron withdrawing nitro group increases the binding affinity 13-fold. Since the opposite result was, in fact, expected, these data suggest that a decrease in electron density at the bridge nitrogen is not always responsible for a decrease in activity. The reason for this anomaly is presently unknown, however, our results indicate that besides the electron density at nitrogen there are other factors contributing to the overall binding affinity of these N-substituted analogues.

Of further interest is the discrepancy between the binding affinities and dopamine reuptake inhibition activity for 2 and 3, with both compounds being more active in the binding experiments than in dopamine uptake. The Ki for the binding affinity of compounds 2 and 3 is 2.6 and 2.8 times smaller, respectively, than its Ki for inhibition of dopamine reuptake. Thus, the possibility exists that these compounds may be capable of countering to some extent the effects of cocaine, and therefore serve as functional "antagonists" of cocaine. [3H]Dopamine uptake experiments were therefore conducted to examine whether 3 was capable of causing a concentration-dependent rightward shift of the cocaine inhibition curve. Surprisingly, no meaningful shift was observed with this compound. Additionally, no rightward shift beyond that expected for two inhibitors acting at the same site was detected when compound 13, which shows a larger spread in binding and uptake potency than 3, was tested in a similar fashion. In contrast, we had found that 7α-methoxypseudococaine, which shows a four-fold spread in binding and uptake potency, was capable of causing a three-fold rightward shift of the cocaine inhibition curve that was about 30 % greater than that expected for two inhibitors acting at the same site. 1a While the interpretation of these data is not straightforward, it is clear that the identification of a cocaine antagonist can not be made by simply identifying discrepancies in the binding and uptake Kis. Hopefully, a better understanding of these issues will result from continued investigations of cocaine's chemistry and biology.

**Acknowledgements**. We are indebted to the National Institute on Drug Abuse for support of our research program.

## **References and Notes**

(1) (a) Simoni, D.; Stoelwinder, J.; Kozikowski, A. P.; Johnson, K. M.; Bergmann, J. S.; Ball, R. G. Methoxylation of Cocaine Reduces Binding Affinity and Produces Compounds of Different Binding and Uptake Activity: Discovery of a Weak Cocaine "Antagonist". *J. Med. Chem.*, in press. (b) Kozikowski, A. P.; Roberti, M.; Johnson, K. M.; Bergmann, J. S.; Ball, R. G. SAR of Cocaine: Further Exploration of Structural Variations at the C-2 Center Provides Compounds of Subnanomolar Binding Potency. *BioMed. Chem. Lett.* 1993, *3*, 1327-1332. (c) Kozikowski, A. P.; Roberti, M.; Xiang, L.; Bergmann, J. S.; Callahan, P. M.; Cunningham, K. A.; Johnson, K. M. Structure-Activity Relationship Studies of Cocaine: Replacement of the C-2 Ester Group by Vinyl Argues against H-Bonding and Pro-

- vides an Esterase Resistant, High-Affinity Cocaine Analogue. *J. Med. Chem.* **1992**, *35*, 4764-4766. (d) Kozikowski, A. P.; Xiang, L.; Tanaka, J.; Bergmann, J. S.; Johnson, K. M. Use of Nitrile Oxide Cycloaddition (NOC) Chemistry in the Synthesis of Cocaine Analogues; Mazindol Binding and Dopamine Uptake Studies. *Med. Chem. Res.* **1991**, *1*, 312-321.
- (2) Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationships of Cocaine Analogues at the Dopamine Transporter. *J. Med. Chem.* **1992**, *35*, 969-981. Abraham, P.; Pitner, J. B.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J.; Carroll, F. I. *N*-Modified Analogues of Cocaine: Synthesis and Inhibition to the Cocaine Receptor. *J. Med. Chem.* **1992**, *35*, 141-144.
- (3) Reith, M. E. A.; Meisler, B. E.; Sersehn, H.; Lajtha, A. Structural Requirements for Cocaine Congeners to Interact with Dopamine and Serotonin Uptake Sites in Mouse Brain and to Induce Stereotyped Behavior. *Biomed. Pharm.* **1986**, *35*, 1123.
- (4) Madras, B. K.; Kamien, J. B.; Fahey, M. A.; Canfield, D. R.; Milius, R. A.; Saha, J. K.; Neumeyer, J. L; Spealman, R. D. N-Modified Fluorophenyltropane Analogs of Cocaine with High Affinity for Cocaine Receptors. *Pharmacol. Biochem. Behav.* **1990**, *35*, 949.
- (5) Olofson, R. A.; Martz, J. T.; Senet, J. P.; Piteau, M.; Malfroot, T. A New Reagent for the Selective, High Yield N-Dealkylation of Tertiary Amines: Improved Syntheses of Naltrexone and Nalbuphine. *J. Org. Chem.* **1984**, *49*, 2081-2082. Baldwin, S. W.; Jeffs, P. W.; Natarajan, S. Preparation of Norcocaine. *Synth. Commun.* **1977**, *7*, 79. Borne, R. F.; Bedford, J. A.; Buelke, J. L.; Craig, C. B.; Hardin, T. C.; Kibbe, A. H.; Wilson, M. C. Biological Effects of Cocaine Derivatives I: Improved Synthesis and Pharmacological Evaluation of Nor-cocaine. *J. Pharm. Sci.* **1977**, *66*, 119.
- (6) Emmons, W. D.; Ferris, A. F. Oxidation Reactions with Pertrifluoroacetic Acid. *J. Am. Chem. Soc.* **1953**, *75*, 4623-4624.
- (7) Achiwa, K.; Yamada, S. Hydrazino Acids and Peptides. A New General Synthesis of L- $\alpha$ -Hydrazino Acids from L- $\alpha$ -Amino Acids. *Tetrahedron Lett.* **1975**, *31*, 2701-2704.
- (8) Wallace, R. G. Hydroxylamine-*O*-sulfonic Acid A Versatile Synthetic Reagent. *Aldrichimica Acta* **1980**, *13*, 3-11. Although compound **7** is a new cocaine analogue, a similar ring closure reaction was described for the intramolecular cyclization of *N*-carbamoyl-*N*-norcocaine to a tricyclic lactam. Fodor, G.; Kovacs, O.; Weisz, I. *Nature* **1954**, *174*, 131.

(Received in USA 13 October 1993; accepted 16 November 1993)